Viewing Study NCT02970318

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 5:02 AM
Ignite Modification Date: 2026-02-25 @ 7:08 PM
Study NCT ID: NCT02970318
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-27
First Post: 2016-11-18
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Sponsor: Acerta Pharma BV
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Lymphocytic Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CLL View
None BTK View
None Bruton Tyrosine Kinase View
None acalabrutinib View
None ACP-196 View